TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT03193853
Completed
This study evaluates efficacy of TAK- 228 and TAK- 117 followed by cisplatin and nab paclitaxel in patients with metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Triple Negative Breast Cancer
Register for Updates
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
NCT00993655
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube ca... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Mercy-Springfield, Springfield, Missouri +49 locations
Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
NCT00146562
Completed
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +5 locations
Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Register for Updates
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
NCT04551950
Completed
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2023
Locations: Stanford Health Care Hospital & Clinics, Stanford, California +12 locations
Conditions: Cervical Cancer
Register for Updates
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
NCT03018080
Completed
The primary objective of this study is to assess the safety and feasibility of the following two regimens: Cohort A) phased regimen of pembrolizumab in which paclitaxel is followed by paclitaxel plus pembrolizumab and Cohort B) concurrent regimen of paclitaxel plus pembrolizumab. The primary safety objective is to evaluate the overall grade 3 or 4 treatment-related adverse event rate for each cohort and compare them to relevant historical controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2023
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Breast - Female, Male Breast Cancer
Register for Updates
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT03840915
Completed
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2023
Locations: Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California +18 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Genetic Predictors of Benefit to Pembrolizumab
NCT02710396
Terminated
The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy. This will be a 3-arm, multi-center, open-label, non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may receive either cohorts 1 and 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2023
Locations: Columbia University, New York, New York +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
NCT01726582
Completed
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy and radiation therapy) that the patient will receive before having surgery to remove the adenocarcinoma. When the patient goes to surgery, the adenocarcinoma that is removed is tested again. The results of that test are used... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: University of Cincinnati Cancer Center, Cincinnati, Ohio +1 locations
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
NCT05794659
Not Yet Recruiting
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: University of Washington, Seattle, Washington
Conditions: Advanced Ovarian Cancer
Register for Updates
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
NCT02530437
Terminated
This phase IB/II trial studies the side effects of taladegib, paclitaxel, carboplatin, and external beam radiation therapy and to see how well they work in treating patients with esophageal or gastroesophageal junction cancer found only in the tissue or organ where it began, and has not spread to nearby lymph nodes or to other parts of the body (localized). Taladegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7, Stage IIB Esophageal Adenocarcinoma AJCC v7, Stage IIIA Esophageal Adenocarcinoma AJCC v7, Stage IIIB Esophageal Adenocarcinoma AJCC v7
Register for Updates
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
NCT04572100
Completed
Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage after therapy and reduce the amount of additional radiotherapy or chemotherapy treatment the participant may need. This study will also examine ways to reduce overall side effects of treatment using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine, and peripheral stem cell transplantation in treating pat... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
07/03/2023
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California
Conditions: Breast Cancer
Register for Updates